Association between persistence of mutations in remission on hematologic recovery following induction chemotherapy in AML patients. (A) Number of mutations in each of the indicated genes found at diagnosis and during remission. (B) VAF of each mutation in each gene during remission. Each data point represents an individual mutation detected in remission. The horizontal dotted line indicates the cutoff used to distinguish between “high” and “low” VAF. See text for details. (C) Cumulative proportion of patients with platelet recovery (≥50 × 109/L) and neutrophil recovery (≥0.5 × 109/L) in patients with persistence of mutations at “high” or “low” VAF compared with those without any detectable mutations in remission. The P values were calculated using the log-rank test.